Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
Adicet Bio, Inc. (NASDAQ: ACET) will host a webcast on December 11, 2022, at 9:00 a.m. EST, to discuss the latest data from its Phase 1 study of ADI-001, targeting relapsed or refractory B-cell NHL.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Event to be webcast on
The event will feature Sattva Neelapu, M.D., Professor in the
Conference Call and Webcast Event
The live webcast of the presentation can be accessed by registering under “Presentations & Events” in the investors section of the Company’s website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To participate via telephone, please join by dialing 1-833-548-0276 (domestic) or 1-646-876-9923 (international) and referencing the conference ID 98173615816.
An archived replay will be available for 30 days following the presentation. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201006019/en/
Investor and Media Contacts
abowdidge@adicetbio.com
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com
Source: